PMID- 9183922
OWN - NLM
STAT- MEDLINE
DCOM- 19970707
LR  - 20071115
IS  - 0040-5957 (Print)
IS  - 0040-5957 (Linking)
VI  - 52
IP  - 1
DP  - 1997 Jan-Feb
TI  - [Heparins and curative treatment of venous thromboembolic disease: 
      meta-analysis].
PG  - 47-52
AB  - Heparin treatment of venous thromboembolic disease has been validated since 1960. 
      Nevertheless no study was sufficient to determine an optimal therapeutic schedule 
      between sub-cutaneous (SC) unfractionated heparin (UFH), intravenous (IV) UFH and 
      low molecular weight heparin (LMWH). One meta-analysis showed a significant risk 
      reduction of recurrent thromboembolic events (OR = 0.58, CI 95 per cent 
      [0.34-0.99]) and a non-significant risk reduction of haemorrhagic events (OR = 
      0.78 [0.40-1.52]) with UFH SC compared to UFH IV, but homogeneity testing was 
      significant (p < 0.001). Some discrepancy was shown between the results of the 
      three metaanalyses which compared LMWH to UFH according to the selection criteria 
      of clinical trials used. With an exhaustive selection, LMWH involved a 
      non-significant risk reduction of recurrent thromboembolic events (OR = 0.66 
      [0.41-1.07], p = 0.09), and a non-significant risk reduction of haemorrhagic 
      events (OR = 0.65 [0.36-1.16], p = 0.15). So no definitive conclusion could be 
      drawn but it seems that UFH can be recommended whatever the administration route 
      or LMWH for deep vein thrombosis treatment.
FAU - Mismetti, P
AU  - Mismetti P
AD  - Unite de Pharmacologie Clinique, CHU de St-Etienne Bellevue, France.
FAU - Laporte-Simitsidis, S
AU  - Laporte-Simitsidis S
FAU - Leizorovicz, A
AU  - Leizorovicz A
FAU - Decousus, H
AU  - Decousus H
LA  - fre
PT  - English Abstract
PT  - Journal Article
PT  - Meta-Analysis
TT  - Heparines et traitement curatif de la maladie veineuse thromo-embolique: 
      meta-analyses.
PL  - France
TA  - Therapie
JT  - Therapie
JID - 0420544
RN  - 0 (Anticoagulants)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 9005-49-6 (Heparin)
SB  - IM
MH  - Anticoagulants/*therapeutic use
MH  - Heparin/*therapeutic use
MH  - Heparin, Low-Molecular-Weight/*therapeutic use
MH  - Humans
MH  - Infusions, Intravenous
MH  - Injections, Subcutaneous
MH  - Meta-Analysis as Topic
MH  - Thromboembolism/*drug therapy
EDAT- 1997/01/01 00:00
MHDA- 1997/01/01 00:01
CRDT- 1997/01/01 00:00
PHST- 1997/01/01 00:00 [pubmed]
PHST- 1997/01/01 00:01 [medline]
PHST- 1997/01/01 00:00 [entrez]
PST - ppublish
SO  - Therapie. 1997 Jan-Feb;52(1):47-52.